Literature DB >> 17653762

Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation.

Naoko Kudo1, Akira Ogose, Tetsuo Hotta, Hiroyuki Kawashima, Wenguang Gu, Hajime Umezu, Tsuyoshi Toyama, Naoto Endo.   

Abstract

Dedifferentiated chondrosarcoma is a rare, highly malignant variant of chondrosarcoma in which a high-grade sarcoma coexists with a low-grade chondroid tumor. We herein review a case of dedifferentiated chondrosarcoma with an osteosarcoma omit component that occurred in the distal femur of a 38-year-old man. We established the cell line (NDCS-1) from a pleural effusion of the metastatic lung tumor. The cell line was characterized by a the G-banded karyotype, polymerase chain reaction (PCR) single-strand conformation polymorphism analysis, spectral karyotyping, and reverse transcriptase PCR (RT-PCR). The tumor exhibited complex karyotypes and a high frequency of chromosomal amplication with p53 mutation. This tumor revealed an osteoblastic and chondroblastic character in vitro and in severe combined immunodeficiency mice. The expression and phosphorylation of platelet-derived growth factor receptor-beta, which seemed to play a major role in the malignant phenotype of chondrosarcoma, was confirmed by RT-PCR and Western blotting. To our knowledge, this is the first report of the establishment of a human dedifferentiated chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653762     DOI: 10.1007/s00428-007-0426-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  61 in total

1.  Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.

Authors:  C Haberler; E Gelpi; C Marosi; K Rössler; P Birner; H Budka; J A Hainfellner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Cytogenetic analysis of dedifferentiated chondrosarcoma.

Authors:  S J Swarts; J R Neff; S L Johansson; J A Bridge
Journal:  Cancer Genet Cytogenet       Date:  1996-07-01

3.  Fibrosarcomatous dedifferentiation of primary and secondary chondrosarcoma. Review of five cases.

Authors:  J M Mirra; R C Marcove
Journal:  J Bone Joint Surg Am       Date:  1974-03       Impact factor: 5.284

4.  A rapid banding technique for human chromosomes.

Authors:  M Seabright
Journal:  Lancet       Date:  1971-10-30       Impact factor: 79.321

5.  Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma.

Authors:  David Gisselsson; Eva Pålsson; Mattias Höglund; Henryk Domanski; Fredrik Mertens; Nikos Pandis; Raf Sciot; Paola Dal Cin; Julia A Bridge; Nils Mandahl
Journal:  Genes Chromosomes Cancer       Date:  2002-02       Impact factor: 5.006

6.  Evidence of an association between 6q13-21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors.

Authors:  J R Sawyer; C M Swanson; J L Lukacs; R W Nicholas; P E North; J R Thomas
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

7.  Expression of PPAR-gamma is correlated with the clinical course of neuroblastoma.

Authors:  Yoko Sato; Hidefumi Sasaki; Yoshihiro Kobayashi; Nobuhiro Haruki; Tatsuya Toyama; Satoshi Kondo; Yoshitaka Fujii
Journal:  J Pediatr Surg       Date:  2003-02       Impact factor: 2.545

Review 8.  Chromosomal changes in a dedifferentiated chondrosarcoma: a case report and review of the literature.

Authors:  D P O'Malley; K E Opheim; T S Barry; D B Chapman; M J Emond; E U Conrad; T H Norwood
Journal:  Cancer Genet Cytogenet       Date:  2001-01-15

9.  Identification of an unusual marker chromosome by spectral karyotyping.

Authors:  B Huang; Y Ning; A N Lamb; C J Sandlin; M Jamehdor; T Ried; J Bartley
Journal:  Am J Med Genet       Date:  1998-12-04

10.  Cytogenetic findings in 19 malignant bone tumors.

Authors:  Y Y Ozisik; A M Meloni; A Peier; O Altungoz; S S Spanier; M M Zalupski; S P Leong; A A Sandberg
Journal:  Cancer       Date:  1994-10-15       Impact factor: 6.860

View more
  17 in total

1.  Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1.

Authors:  Rieko Oyama; Fusako Kito; Mami Takahashi; Marimu Sakumoto; Kumiko Shiozawa; Zhiwei Qiao; Rei Noguchi; Takashi Kubo; Shunichi Toki; Fumihiko Nakatani; Akihiko Yoshida; Akira Kawai; Tadashi Kondo
Journal:  Hum Cell       Date:  2019-02-08       Impact factor: 4.174

2.  An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing.

Authors:  Jolieke G van Oosterwijk; Jacqueline R M Plass; Danielle Meijer; Ivo Que; Marcel Karperien; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2014-10-21       Impact factor: 4.064

3.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

4.  Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma.

Authors:  Makoto Nakagawa; Masayuki Yamaguchi; Makoto Endo; Yukino Machida; Ayuna Hattori; Fumie Tanzawa; Shinji Tsutsumi; Issay Kitabayashi; Akira Kawai; Fumihiko Nakatani
Journal:  J Bone Oncol       Date:  2022-04-16       Impact factor: 4.491

5.  BMPR2-pSMAD1/5 signaling pathway regulates RUNX2 expression and impacts the progression of dedifferentiated chondrosarcoma.

Authors:  Kang Yang; Xiao-Dong Tang; Wei Guo; Xiao-Long Xu; Ting-Ting Ren; Cong-Min Ren; Shi-Dong Wang; Xing Bao; Fan Zhang; Kun-Kun Sun
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

6.  Explant culture of sarcoma patients' tissue.

Authors:  Roman Muff; Sander M Botter; Knut Husmann; Joelle Tchinda; Philomina Selvam; Franziska Seeli-Maduz; Bruno Fuchs
Journal:  Lab Invest       Date:  2016-04-25       Impact factor: 5.662

7.  Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.

Authors:  Makoto Nakagawa; Fumihiko Nakatani; Hironori Matsunaga; Takahiko Seki; Makoto Endo; Yoko Ogawara; Yukino Machida; Takuo Katsumoto; Kazutsune Yamagata; Ayuna Hattori; Shuhei Fujita; Yukiko Aikawa; Takamasa Ishikawa; Tomoyoshi Soga; Akira Kawai; Hirokazu Chuman; Nobuhiko Yokoyama; Suguru Fukushima; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Takeshi Hirose; Toshifumi Fujiwara; Nokitaka Setsu; Yoshihiro Matsumoto; Yukihide Iwamoto; Yasuharu Nakashima; Issay Kitabayashi
Journal:  Oncogene       Date:  2019-08-12       Impact factor: 9.867

8.  Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.

Authors:  Twinkal C Pansuriya; Ronald van Eijk; Pio d'Adamo; Maayke A J H van Ruler; Marieke L Kuijjer; Jan Oosting; Anne-Marie Cleton-Jansen; Jolieke G van Oosterwijk; Sofie L J Verbeke; Daniëlle Meijer; Tom van Wezel; Karolin H Nord; Luca Sangiorgi; Berkin Toker; Bernadette Liegl-Atzwanger; Mikel San-Julian; Raf Sciot; Nisha Limaye; Lars-Gunnar Kindblom; Soeren Daugaard; Catherine Godfraind; Laurence M Boon; Miikka Vikkula; Kyle C Kurek; Karoly Szuhai; Pim J French; Judith V M G Bovée
Journal:  Nat Genet       Date:  2011-11-06       Impact factor: 41.307

9.  Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

Authors:  J G van Oosterwijk; M A J H van Ruler; I H Briaire-de Bruijn; B Herpers; H Gelderblom; B van de Water; J V M G Bovée
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

10.  Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone.

Authors:  Jolieke G van Oosterwijk; Danielle de Jong; Maayke A J H van Ruler; Pancras C W Hogendoorn; P D Sander Dijkstra; Carla S P van Rijswijk; Isidro Machado; Antonio Llombart-Bosch; Karoly Szuhai; Judith V M G Bovée
Journal:  BMC Cancer       Date:  2012-08-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.